NEW YORK (GenomeWeb) – Illumina and PierianDx have forged a non-exclusive, multi-year partnership to develop cancer sequencing products.
Under the terms of the agreement, PierianDx will provide variant interpretation and reporting, based on its Clinical Genomics Workspace platform and Clinical Genomics Knowledgebase, for Illumina's TruSight Tumor 170 and TruSight Oncology 500 research assays, as well as for future in vitro diagnostic products.
The agreement "has the potential to provide laboratories clinically-optimized solutions that may accelerate assay validation and deployment and simplify genomic interpretation," Rakesh Nagarajan, executive chairman of PierianDx, said in a statement.
PierianDx CEO Michael Sanderson added that the agreement would also help the firm accelerate its US and international strategic plans.
"The combination of Illumina’s comprehensive tumor profiling assays with Pierian Dx’s variant interpretation and reporting solutions will provide customers with a seamless experience," said Garret Hampton, executive vice president of clinical genomics at Illumina.
Illumina will be responsible for distributing the oncology products and packaged solutions. Labs that purchase the oncology assays with PierianDx informatics will have access to the PierianDx Clinical Genomics Workspace for analysis, interpretation, and reporting of results and will be able to get additional services from PierianDx, such as medical sign-out and electronic medical record integration.